EXAS · CIK 1124140
What Exact Sciences Corporation told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for EXAS. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- third-party / Medicare reimbursement coveragemedium
Commercial success of Cologuard Plus, Oncodetect MRD, Cancerguard MCED and other tests depends on obtaining and maintaining adequate reimbursement from Medicare/MolDX, managed care, and commercial payers; coverage is not guaranteed.
“Additionally, successful commercialization of our newly developed products, including our Cologuard Plus test, our Oncodetect MRD test, and our Cancerguard MCED test, will also depend on our ability to obtain and maintain reimbursement from government insurance plans, managed care organizations, and commercial insurance plans at adequate reimbursement rates.”
SEC filing →As of 2026 - GDPR / APPI data protectionlow
International commercialization (Oncotype in ~120 countries, including Japan) subjects Exact Sciences to GDPR, Japan's APPI and other data-protection regimes that require significant compliance effort and can sanction or halt use of personal/health data.
“Further, we are required to comply with international, national, and provincial personal data protection laws and regulations, including the European Union's (“E.U.”) General Data Protection Regulation (“GDPR”) and Japan's Act on the Protection of Personal Information (“APPI”).”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Phillips-Medisize, LLC
“For example, Phillips-Medisize, LLC (“Phillips”) is now our sole source provider of Cologuard test kit manufacturing”
Cited →“our OncoExTra test is currently only validated to be performed on Illumina's sequencing platform, and the MRD and MCED tests we launched in 2025 will similarly utilize this platform.”
Cited →Hamilton Company
“We also rely on Hamilton Company (“Hamilton”) to provide us laboratory equipment and related supplies (such as racking and pipette tips) necessary to perform certain critical steps in our clinical laboratory tests, including our Cologuard and precision oncology tests.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch